Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm sure they already know with our "close working relationship" we developed with BARDA and the NIH on R18..... Pfffft.
This company is a joke and the leadership is the punchline!
8 years too late. Now we are desperate.
Will pass through 52 week low before next Friday. PSTI HAS The Corona Virus! Pfffft at trying to treat it....
Nothing but pumpers pumping here anymore- can't inflate a terd with holes in it.
Used to think Gary was real, now confirmed as pumper #5.
DOA.
REJECTS, REJECTED, THROWN OUT, JUNK DATA AND DESIGN. ABYSMAL AND ABJECT FAILURE.
BARDA.... Pfffft. How can this be?!?!?!
You've claimed this to be the holy Grail of approvals for this fast tracked nuclear cure. And now in the face of nuclear holocaust threats the federal government doesn't want to approve or fund this miracle cure; of which you've claimed hope and promise for? As has been stated and printed before... this company couldn't sell a cancer cure in a hospice center or a nuclear catastrophe remedy at Chernobyl. This may be the death nail for this POS stem cell scam. No question the next dilution is coming deep and wide!!!
BARDA BOOM BARDA BUST!!!!! Bwaaahaaaaa, GO NEUPOGEN & NEULASTA, eh SPIDEYBOY??? BWAAAAAHAAAAAAAAAA. "Superior" spidey the pharmacy tech says.....
All we can do is HOPE! STERoids won't even stimulate psti from falling faster than the market average....
Will you leave your practice?!
Forgive the Capitalist in me, but if THAT is this management's best 'Pricing Strategy', it explains perfectly why this merry band of misfits has not been successful to date!
Might as well be a Not-For-Profit charity company at that price... How will the EVER repay stockholders with those numbers?!?!
Moreover, if you don't seek your highest price with your first launch, you'll NEVER be able to raise it going forward...
Not even with A Cancer Cure.
@fdawillapprove... The Depth and Detail of your Deceipt and Deception are impressive, I must say. You forgot your legal disclaimer of IMO. Further too, your 'all investors are clueless but you' slant, is laughable (insert belt Laugh), what you describe is material events, and somehow, you are privy to it?!?! Is that what you imply here!?!?! Pfffft. I guess that's why the ATM is still flooding the market with $4/+/- shares... Instead of buying its shares back in the open market, when this pending giddy Up deal... Brilliant management fur sure. Go soak your HEAD DB!
Somebody slipped another fictitious new username past ihub... The 'cult of personality' reply is a dead giveaway for good ole Jackie Allo. Running out of material, never planned to work this account for so long.
PSTI Friday SP run up ready to begin. Monday slip'n'slide, watering up.
Just checked on the ATM; it's plugged in, full of new shares to flood and dilute today!!
See you at $4.35 this afternoon.
It means nobody trusts the run. Shorts are just getting their money back and we'll play The channel for another year with no news
To bad we can't make it in our amazingly worthless 3D bioreactors. They probably need more than 75ml, though.... Pffft.
Curious to know whether BARDA'S Delay is based ON INFERIOR Safety, Efficacy or BOTH!?...
2021/2022 nothing but BABLING FOOLS til then.
Wheres that enrollment update? ANY noise outta the island of misfit TOYS IS WAY OVER DUE
EXCLUSIVE! footage from WGAS just dropped!
Leadership outlines companies CLI 'market access' data and hidden camera footage of KOL reactions to PAD data during market access interviews! See it Live
All of this amazing news and breakthrough technology closely followed on WGAS, CHANNEL 9, The Who Gives A Shit channel!! Update tonight at 11!
One thing is known for sure. You clearly Do Not know anything about psti and pending news. Next week will be no different.
"The Family Office Network" interview at JPM...
If THAT doesn't PERFECTLY rank the value of PSTI at the World's most important analyst meeting, nothing does...............
Think about it. TFON? Really? Nobody else cares! It would have been better not to even attend. Imo.
Take a look at MESO if you want an example of a company on the verge of liftoff. No joke. They will LAP psti.
Anyone take notes from Yakys presentation today?
Just like psti, no date , no time... Maybe NOT.
I GET THE IMPRESSION THIS MEANS HE'S PRESENTING AT THE PSTI BOOTH ON HIS LAPTOP TO ANYONE THAT WILL LISTEN.
Now ask yourself, is there really anything material going on here?!?!.... Laughable!! .
10 Top Penny Stocks to Watch This Week as Markets Breach Record Highs
https://moneymorning.com/2020/01/10/10-top-penny-stocks-to-watch-this-week-as-markets-breach-record-highs/
Looks like allo. got a new profile for Christmas. January 6https://tse2.mm.bing.net/th?id=OGC.b92a1c9f1bb94843580ca97d425d38eb&pid=Api&rurl=https%3a%2f%2fmedia.giphy.com%2fmedia%2f3oEjHXTdZtYRmhWzny%2fgiphy.gif&ehk=%2bOhhn7dpnU1qs22sQNztb9QsV9p9%2b4rwuc4EncVoHe4%3d th actually.
Seriously though, the implications of NOT receiving a BARDA deal are staggering for psti.
One could only surmise that underwhelming efficacy/safety and/or in-threatre logistics could not be overcome.
Anything but a contract generating revenue will lead to an institutional exodus the likes of which have never been seen here.
Investors have had enough, it's do or die.
Sorry.
No matter what, the bumbling keystone cops, Yaky and Zami get their pay restored come June. Results or NOT. What a sweet deal for them... Again.
Go back and read the fine print.
Double the market cap by June, Pfffft.
So much for First things FIRST....
“....the first being a safe, effective, and efficient alternative to bone marrow transplantation,” according to Pluristem chairman and CEO, Zami Aberman."
“We intend to develop this technology platform into a functional stem cell production system for the treatment of a variety of indications; the first being a safe, effective, and efficient alternative to bone marrow transplantation,” according to Pluristem chairman and CEO, Zami Aberman.
TRENDING
PORTFOLIO
PEOPLE
MARKET NEWS
STOCK IDEAS
DIVIDENDS
INVESTING STRATEGY
REITS
WALL STREET BREAKFAST
ON THE MOVE
DIVIDEND NEWS
MARKET OUTLOOK
?
Probio Invest
Follow
Short Ideas
Healthcare
Israel
Pluristem Therapeutics: Questionable Ethics And Bucket Shop Coverage
Feb. 02, 2015 4:37 PM ETPluristem Therapeutics Inc. (PSTI)CVM, EVSNF, FLUX...20 Comments
This article is exclusive for subscribers
Summary
Pluristem has a long history of ethically questionable reporting to investors.
Stock price jumps ostensibly on analysis published by a discredited bucket shop.
Heavy dilution is imminent and could have a significant negative effect on the share price.
Top executives have zero educational and professional experience in the biotech field.
The author has not reached out to PSTI management for comments. Phone calls made to Acceleron Equity Research were not returned.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases. Since Jan 28th, Pluristem has jumped over 30% on no material news except for one-page coverage update from Acceleron Equity Research.
Rinse and Repeat. Always good to short joke-ster's money. This pig should channel nicely, daily fire the distant future. Cha Ching, badda-bing.
Appreciate the donations today. Was great to short out some Christmas money! Will be taking more and playing the channel for months to come!
Jesus is the Reason for The Season!
Wow, doesn't seem wise to tax loss sell in tbe midst of the imminent Share Price breakout Betty and the run up to $4+ as you see by year end....
Do they not see it the way you do?!
Bwahaaahaaaa, last week you said $3.80 and beyond, "better get on-board", Looking to "Double Down"
??????
"For PLX-PAD in CLI however we have a guaranteed potential EU approval data date for April-June 2020."
Oh my scientific spideyboy...., that's quite a stratement right there! Great use of 'hope' in your further analysis too.
Don't you have some scripts to fill? There is someone in the drive through rigt now... Go, go.
Liar, liar, pants on fire, Aldo.
Estimated Study Completion Date:
July 1, 2021
Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)
?The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03451916
Recruitment Status : Recruiting
First Posted : March 2, 2018
Last Update Posted : April 30, 2019
See Contacts and Locations
Sponsor:
Pluristem Ltd.
Information provided by (Responsible Party):
Pluristem Ltd.
Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record
Study Description
Go to ?
Brief Summary:
The objectives of this study are to assess the efficacy, safety, and tolerability of PLX-PAD intramuscular administration for the treatment of muscle injury following arthroplasty for HF.
Condition or disease Intervention/treatment Phase Hip FractureDrug: PLX-PADDrug: PlaceboPhase 3
Detailed Description:
This will be a Phase III, multinational, randomized, double-blind, placebo-controlled study, assessing the efficacy, safety, and tolerability of intramuscular (IM) administration of allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for HF as compared to placebo treatment. Both treatment arms will receive standard of care treatment per local practice.
The study will comprise 2 periods:
Main study period - from Screening to 52 weeks post-treatment. During this period, the subjects will have the following study visits: Screening, Day 0 (treatment and surgery day), Day 1, Day 5, Week 6, Week 12, Week 26 and Week 52.
Safety follow-up period - from Week 52 to Week 104. During this safety follow-up period, there will be a phone call visit at Week 104, and only related serious adverse events (SAEs) and new malignancy adverse events will be collected.
The main study period will comprise 4 periods:
Screening and pre-surgery time
Surgery and treatment with PLX-PAD or placebo (Day 0)
Hospital follow-up until Day 5±1, at least
Follow-up period up to 52 weeks following study treatment administration. Subjects will be assessed for study eligibility before the emergency surgery for HF. After being found eligible, subjects will be randomized using a 1:1 allocation scheme to either 150×106 PLX-PAD cells or to placebo treatment, respectively. Within 48 hours of admission and up to 72 hours following fracture, subjects will undergo HA or THA. During the surgical procedure, the subjects will receive the investigational product in accordance with the treatment group to which they were randomized. Thereafter, visits will be conducted at Days 1 and 5±1, and at Weeks 6, 12, 26, 52 and 104.
Study Design
Go to ?
Study Type :Interventional (Clinical Trial)Estimated Enrollment :240 participantsAllocation:RandomizedIntervention Model:Sequential AssignmentIntervention Model Description:, subjects will be randomized using a 1:1 allocation scheme to either 150×106 PLX-PAD cells or to placebo treatment, respectivelyMasking:Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose:TreatmentOfficial Title:Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip FractureActual Study Start Date :July 26, 2018Estimated Primary Completion Date :July 1, 2020
Estimated Study Completion Date :July 1, 2021
Resource links provided by the National Library of Medicine?
MedlinePlus related topics: Fractures Hip Injuries and Disorders
Drug Information available for: PlasmaLyte
U.S. FDA Resources
PLX-PAD Estimated Study Completion Date:
July 1, 2021...
THAT'S 2 YEARS AND 2 DILUTIONS AWAY FOLKS.
Prepare to be DISAPPOINTED!! Imo. See this as psti's early, deflected, expectation management. As has been long suspected, poor trial design, has led to poor enrollment and likely sub optimal results... Amateur leadership, data will be ripe with excuses... See the writing on the wall here:
Results of PSTI P3 trials will be:
Further evaluation needed: Therapeutic angiogenesis in the treatment of PAD https://vascularnews.com/further-evaluation-needed-therapeutic-angiogenesis-in-the-treatment-of-pad/
Pluristem Therapeutics: Questionable Ethics And Bucket Shop Coverage
Seeking Alpha
Feb. 2, 2015 4:37 PMPluristem Therapeutics Inc. (PSTI)CVM, EVSNF, FLUX
Summary
Pluristem has a long history of ethically questionable reporting to investors.
Stock price jumps ostensibly on analysis published by a discredited bucket shop.
Heavy dilution is imminent and could have a significant negative effect on the share price.
Top executives have zero educational and professional experience in the biotech field.
The author has not reached out to PSTI management for comments. Phone calls made to Acceleron Equity Research were not returned.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases. Since Jan 28th, Pluristem has jumped over 30% on no material news except for one-page coverage update from Acceleron Equity Research.
But these guys know the best!!!
Pluristem Therapeutics (NASDAQ:PSTI) Will Have To Spend Its Cash Wisely
https://finance.yahoo.com/news/pluristem-therapeutics-nasdaq-psti-spend-160626926.html
'I Got Nothing for My Money': Patients, Doctors Question 'Stem Cell' Therapy
https://www.nbcbayarea.com/news/local/I-Got-Nothing-for-My-Money-Patients-Doctors-Question-Stem-Cell-Therapy-564936702.html